BETWEENClinical Research Agreement • January 30th, 2006 • Northern Way Resources, Inc. • Metal mining • California
SIMBECClinical Research Agreement • August 2nd, 2000 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations
EXHIBIT 10.22 CLINICAL RESEARCH AGREEMENT Agreement made as of 1st November 1995 between The Royal Free Hampstead (NHS) Trust, a not-for-profit corporation having a principal place of business at Pond Street, Hampstead, London, England ("Trust"),...Clinical Research Agreement • December 5th, 1996 • Photoelectron Corp • Electromedical & electrotherapeutic apparatus
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • July 15th, 2009
This Agreement, effective as of _____________, is made between XOMA CORPORATION, 2910 Seventh Street, Berkeley, California 94710 ("XOMA") and THE UNIVERSITY OF TEXAS ________, a component of The University of Texas System ("Institution"), for the purpose of conducting a clinical study as set forth in protocol # , entitled _______________ ("Protocol").
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • March 17th, 2008 • Mannatech Inc • Medicinal chemicals & botanical products • Texas
THIS Clinical Research Agreement is entered into on the 3rd day of January, 2007 by and between St. George’s Hospital Medical School (trading as St George’s, University of London), an exempt charity organized and existing under the laws of the United Kingdom, with its principal offices located at Cranmer Terrace, London SW17 ORE (hereinafter referred to as “SGUL”) and Mannatech, Inc., a corporation organized and existing under the laws of the State of Texas, USA, with its principal office located at 600 S. Royal Lane, Suite 200, Coppell, Texas 75019 (hereinafter referred to as “MANNATECH”), jointly referred to as the Parties.
Clinical Research AgreementClinical Research Agreement • July 15th, 2009 • Texas
THIS AGREEMENT is entered into by and between MATRIX PHARMACEUTICAL, INC., with its office and place of business at 1430 O'Brien Drive, Menlo Park, Ca. 94025 ("Sponsor") and The University of Texas _______, _________, ____________, TX _______, ("Research Organization").
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • July 12th, 2021 • South Australia
A The Parties have identified a particular clinical research activity as outlined in the Schedule (‘the Study’) in which they desire to collaborate.
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • July 15th, 2009
This Agreement, effective as of ____________, is made between Genentech, Inc. ("Genentech"), 460 Point San Bruno Boulevard, South San Francisco, California 94080, and The University of Texas _________ ("Study Center") Dallas, Texas (collectively the "Parties") for the purpose of conducting clinical research. Citations to the Code of Federal Regulations ("C.F.R.") in this Agreement are citations to regulations governing investigations of new drugs.
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • July 15th, 2009 • Texas
This is an Agreement made by and between Boehringer Ingelheim Pharmaceuticals, Inc., having its principal office at 900 Ridgebury Road, Ridgefield, Connecticut 06877 (hereinafter called "BIPI") and The University of Texas [Component] (hereinafter called "INSTITUTION") having its principal office at [Component address], a Component Institution of The University of Texas System (hereinafter called "SYSTEM").
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • March 20th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
This Clinical Research Agreement (“Agreement”) is entered into this 5th day of November, 2013 (“Effective Date”) by and between ARCA biopharma Inc. (“Sponsor”), a Delaware corporation with offices at 11080 CirclePoint Road, Suite 140, Westminster, CO 80020, and Duke University (“Duke”), a nonprofit research, education and healthcare institution with an office at 2400 Pratt Street, Durham, North Carolina 27705 (individually, a “Party” and collectively, the “Parties”).
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • March 12th, 2019 • Agile Therapeutics Inc • Pharmaceutical preparations • New Jersey
THIS CLINICAL RESEARCH AGREEMENT (CRA or Agreement) is entered into effective as of October 26, 2018, between TKL Research, Inc., having its principal place of business at One Promenade Boulevard, Suite 1101/1201, Fair Lawn, New Jersey 07410 (TKL) and Agile Therapeutics, Inc. (Sponsor) having its principal place of business at 101 Poor Farm Road, Princeton, New Jersey 08540 (Sponsor) (together the “Parties”).
CLINICAL RESEARCH AGREEMENTClinical Research Agreement • February 19th, 2020 • Cryolife Inc • Surgical & medical instruments & apparatus
This Clinical Research Agreement (“Agreement”) is entered into this 10th day of October, 2019, (“Effective Date”) by and between CryoLife, Inc. (“Sponsor”), a corporation with its principal place of business at 1655 Roberts Boulevard, NW, Kennesaw, Georgia 30144, and Duke University, a tax-exempt research and educational institution acting for and on behalf of its Duke Clinical Research Institute (“Duke”), with an office at 300 West Morgan Street, Suite 800, Durham, North Carolina 27701 (individually, a “Party” and collectively, the “Parties”).
